Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its price objective increased by JPMorgan Chase & Co. from $165.00 to $167.00 in a report published on Wednesday morning,Benzinga reports. JPMorgan ...

The firm owned 57,234 shares of the biotechnology company’s stock after ... restated a “buy” rating and issued a $109.00 price objective (down previously from $111.00) on shares of Merus ...

Bioxyne lifts revenue 77% QoQ; Radiopharm listed on the Nasdaq in the December quarter; Tryptomine hits key milestones; Quarterly season is nearing its end, triggering a rush from ...

PHILADELPHIA and VANCOUVER, British Columbia - BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in immunotherapies for cancer care, announced today its plans to conduct ...

By treating DNA as a language, Brian Hie’s “ChatGPT for genomes” could pick up patterns that humans can’t see, accelerating ...

Instead of encouraging people to buy things they don’t need, how can we creatively and intuitively deliver what they do need? Adapted from Nonlinear: Navigating Design With Curiosity and Conviction ...

About Portage Biotech, Inc. Portage Biotech is a clinical-stage immuno ... statements regarding the Company’s business strategy, plans and objectives of management for future operations and those ...

The Company’s investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies. The Company will seek to achieve its objective by investing ...

On January 23, 2025, the Hubbis Digital Dialogue convened leading voices in the wealth management industry to discuss global ...

President Ursula von der Leyen presented the European Commission's plan to boost Europe's competitiveness and turn it into a place where future ...